⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
globenewswire.com
SNDX
Syndax Announces Participation in November Investor Conferences
globenewswire.com
SNDX
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
globenewswire.com
SNDX
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX